Skip to main content

Tax receipts

Your 2020-2021 tax receipt will be sent mid-July. Contact us if you need to update your details.

Contact us

Our objective

Research undertaken within our Group is focused on determining the mechanisms underlying clot formation in healthy individuals; applying this knowledge to better understand the mechanisms leading to platelet hyperactivity and pathological blood clot formation; and ultimately development of safer and more effective therapies to treat cardiovascular diseases, including heart attack, stroke, diabetes and the metabolic syndrome.

Our impact

Atherothrombosis is arguably Australia’s greatest healthcare problem, affecting over 50% of the adult population. Despite intense investigation over the last 40 years into the discovery and development of more effective antithrombotic drugs, the impact of these therapies on mortality rates has remained disappointingly low. This situation is likely to worsen in the future due to the rapidly growing incidence of obesity, diabetes and the metabolic syndrome – diseases that are typically more resistant to the benefits of “classical” antithrombotic therapy. The comprehensive research approach adopted by our Group is designed to identify and target thrombosis risk in such diseases.

EOFY tax receipts will be sent mid-July

Contact us